A Phase 2 clinical trial of MRG-106 in mycosis fungoides (MF) patients.

Trial Profile

A Phase 2 clinical trial of MRG-106 in mycosis fungoides (MF) patients.

Planning
Phase of Trial: Phase II

Latest Information Update: 14 Mar 2018

At a glance

  • Drugs Cobomarsen (Primary)
  • Indications Cutaneous T cell lymphoma; Mycosis fungoides; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Mar 2018 According to a miRagen Therapeutics media release, study is expected to start in the second half of 2018.
    • 02 Feb 2018 According to a miRagen Therapeutics media release, successful outcome for the primary endpoint of this clinical trial could allow the company to apply for accelerated approval.
    • 08 Nov 2017 According to a miRagen Therapeutics media release, data from the study is anticipated in 2019/2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top